Cassava Sciences, Inc.
SAVA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.05 | -0.02 | -0.03 |
| FCF Yield | -107.04% | -61.06% | -47.29% | -21.31% |
| EV / EBITDA | 0.14 | -0.15 | 0.42 | -0.39 |
| Quality | ||||
| ROIC | -97.03% | -77.08% | -35.49% | -12.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 4.80 | 0.84 | 1.02 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -41.96% | -2.76% | -53.07% | -873.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.91 | 1.27 | 2.68 | 7.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2,522.32 | -1,126.98 | 0.00 |